About immatics nv - IMTX
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.
IMTX At a Glance
Immatics NV
Paul-Ehrlich-Strasse 19
Tuebingen, Baden Wuerttemberg 72076
| Phone | 49-7071-5397-0 | Revenue | 58.38M | |
| Industry | Biotechnology | Net Income | -104,861,726.80 | |
| Sector | Health Technology | Employees | 343 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
IMTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.529 |
| Price to Book Ratio | 3.585 |
| Price to Cash Flow Ratio | 43.039 |
| Enterprise Value to EBITDA | -4.021 |
| Enterprise Value to Sales | 7.121 |
| Total Debt to Enterprise Value | 0.091 |
IMTX Efficiency
| Revenue/Employee | 170,195.333 |
| Income Per Employee | -305,719.32 |
| Receivables Turnover | 9.212 |
| Total Asset Turnover | 0.117 |
IMTX Liquidity
| Current Ratio | 2.87 |
| Quick Ratio | 2.87 |
| Cash Ratio | 2.72 |
IMTX Profitability
| Gross Margin | N/A |
| Operating Margin | -190.499 |
| Pretax Margin | -179.628 |
| Net Margin | -179.628 |
| Return on Assets | -21.002 |
| Return on Equity | -44.047 |
| Return on Total Capital | -36.584 |
| Return on Invested Capital | -41.652 |
IMTX Capital Structure
| Total Debt to Total Equity | 15.281 |
| Total Debt to Total Capital | 13.255 |
| Total Debt to Total Assets | 6.745 |
| Long-Term Debt to Equity | 5.686 |
| Long-Term Debt to Total Capital | 4.932 |